2004
DOI: 10.1097/00004850-200411000-00007
|View full text |Cite
|
Sign up to set email alerts
|

Aripiprazole and neuroleptic malignant syndrome

Abstract: Aripiprazole, an atypical antipsychotic with a novel method of action, has only recently been awarded a license in the UK. We report our first patient to receive this drug, who had treatment-resistant schizophrenia and developed neuroleptic malignant syndrome (NMS) with aripiprazole. To our knowledge, this is the first published case report involving aripiprazole and NMS in a potentially fatal medical emergency. Further experience with this drug should indicate whether this is an isolated case (as described wi… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

1
16
0
1

Year Published

2005
2005
2021
2021

Publication Types

Select...
5
2
1

Relationship

0
8

Authors

Journals

citations
Cited by 47 publications
(18 citation statements)
references
References 7 publications
1
16
0
1
Order By: Relevance
“…19,23 The NIC episodes in this series pursued a relatively benign clinical course. In most cases, re-challenge with antipsychotics only 3 days after the NIC had resolved was uneventful.…”
Section: Discussionmentioning
confidence: 95%
See 2 more Smart Citations
“…19,23 The NIC episodes in this series pursued a relatively benign clinical course. In most cases, re-challenge with antipsychotics only 3 days after the NIC had resolved was uneventful.…”
Section: Discussionmentioning
confidence: 95%
“…Novel antipsychotics including risperidone, 26 aripiprazole, 23 and zotepine, 24 however, have also been implicated. Neuroleptics induce a cataleptic state with posturing, rigidity, and immobility in rodents.…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…41,55 Despite its good overall safety profi le, clinical monitoring of cardiovascular, metabolic, and neurological side effects is still indicated in patients treated with aripiprazole. Rare case reports of keto-acidosis, 58 elevation of triglycerides, 59 neuroleptic malignant syndrome, 60 and parkinsonism 61 have been published, although not necessarily in bipolar disorder.…”
Section: Safety and Tolerabiltymentioning
confidence: 99%
“…First-generation antipsychotics (ie, haloperidol, fluphenazine, chlorpromazine) are some of the common medications that have been associated with NMS; however, NMS has also been reported with second-generation antipsychotic agents such as risperidone, olanzapine, clozapine, quetiapine, ziprasidone, and aripiprazole. [1][2][3][4][5][6][7][8][9][10][11][12][13] The risk of developing NMS is considered greatest in the first 2 weeks after initiating therapy and has also been associated with rapid dose escalation. 14,15 Early recognition, diagnosis, and treatment are keys in preventing NMS-related death.…”
mentioning
confidence: 99%